{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:27:08Z","timestamp":1790746028796,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020180","name":"Japanese Society of Allergology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.anai.2025.06.017","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:45:21Z","timestamp":1750387521000},"page":"537-546.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-652X","authenticated-orcid":false,"given":"Yuto","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Kritikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2025.06.017_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.02.011","article-title":"Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma","volume":"2","author":"Luskin","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.06.017_bib0004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/PPA.S103043","article-title":"Clinical factors affecting quality of life of patients with asthma","volume":"10","author":"Uchmanowicz","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","article-title":"The impact of asthma exacerbations on health-related quality of life in moderate-to-severe asthma patients in the UK","volume":"16","author":"Lloyd","year":"2007","journal-title":"Prim Care Respir J"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2025.06.017_bib0007","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11136-014-0801-x","article-title":"A qualitative study of the impact of severe asthma and its treatment indicateing that treatment burden is neglected in existing asthma assessment scales","volume":"24","author":"Hyland","year":"2015","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0008","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11136-016-1435-y","article-title":"Health-related quality of life associated with systemic corticosteroids","volume":"26","author":"Sullivan","year":"2017","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.anai.2025.06.017_bib0009","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.anai.2025.06.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2025.06.017_bib0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.06.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12054","article-title":"Predictors of asthma-related quality of life in a large cohort of asthmatics: a cross-sectional study in a secondary care center","volume":"11","author":"Louis","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the glucocorticoid toxicity index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2025.06.017_bib0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.anai.2025.06.017_bib0016","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/02770903.2024.2366523","article-title":"Asthma Remission one, none and one-hundred thousand: the relevance of the patient\u2019s view","volume":"61","author":"Bonini","year":"2024","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0017","doi-asserted-by":"crossref","first-page":"00497","DOI":"10.1183\/23120541.00497-2020","article-title":"What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance","volume":"7","author":"Clark","year":"2021","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00606-2022","article-title":"Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)","volume":"61","author":"Khaleva","year":"2023","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2025.06.017_bib0019","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jaip.2021.11.035","article-title":"\u201cNothing about us without us\u201d - What matters to patients with severe asthma?","volume":"10","author":"McDonald","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.anai.2025.06.017_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.rmed.2017.10.010","article-title":"Health-related quality of life in asthma patients - a comparison of 2 cohorts from 2005 and 2015","volume":"132","author":"Sundh","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0024","doi-asserted-by":"crossref","first-page":"00261","DOI":"10.1183\/23120541.00261-2024","article-title":"Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years","volume":"10","author":"Fyles","year":"2024","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.anai.2025.06.017_bib0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.06.017_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaip.2024.10.041","article-title":"Early treatment response to mepolizumab predicts clinical remission in severe eosinophilic asthma","volume":"13","author":"Hamada","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00782-2024","article-title":"Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma","volume":"65","author":"Hamada","year":"2025","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2025.06.017_bib0028","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.anai.2025.06.017_bib0029","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1378\/chest.115.5.1265","article-title":"Validation of a standardized version of the Asthma Quality of Life Questionnaire","volume":"115","author":"Juniper","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.anai.2025.06.017_bib0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.anai.2022.12.002","article-title":"The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma","volume":"130","author":"Sher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific Quality of Life Questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0032","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1378\/chest.121.6.1824","volume":"121","author":"Juniper","year":"2002","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.anai.2025.06.017_bib0033","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0034","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","article-title":"Constructing a control group using multivariate matched sampling methods that incorporate the propensity score","volume":"39","author":"Rosenbaum","year":"1985","journal-title":"Am Stat"},{"issue":"24","key":"10.1016\/j.anai.2025.06.017_bib0035","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"9842","key":"10.1016\/j.anai.2025.06.017_bib0036","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2025.06.017_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.908837","article-title":"Health-related quality of life in adult patients with asthma according to asthma control and severity: a systematic review and meta-analysis","volume":"13","author":"Oh","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0038","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jaip.2018.02.002","article-title":"Anxiety, depression, and asthma control: changes after standardized treatment","volume":"6","author":"Sastre","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2025.06.017_bib0039","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/JAA.S403296","article-title":"Relationship between the response to antibody therapy and symptoms of depression and anxiety disorders in patients with severe asthma","volume":"16","author":"Plank","year":"2023","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaip.2024.01.020","article-title":"Treatable traits in asthma: the importance of extrapulmonary traits-GERD, CRSwNP, atopic dermatitis, and depression\/anxiety","volume":"12","author":"McDonald","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00861-2024","article-title":"Integrating hot topics and implementation of treatable traits in asthma","volume":"64","author":"Gibson","year":"2024","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.anai.2025.06.017_bib0042","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.jaip.2024.06.019","article-title":"Understanding breathlessness burden and psychophysiological correlates in asthma","volume":"12","author":"Lewthwaite","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0043","doi-asserted-by":"crossref","first-page":"00442","DOI":"10.1183\/23120541.00442-2022","article-title":"Adverse perception of cough in patients with severe asthma: a discrete choice experiment","volume":"9","author":"Holmes","year":"2023","journal-title":"ERJ Open Res"},{"issue":"7","key":"10.1016\/j.anai.2025.06.017_bib0044","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1080\/02770903.2025.2472356","article-title":"The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma","volume":"62","author":"H\u00e5kansson","year":"2025","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.anai.2025.06.017_bib0045","doi-asserted-by":"crossref","first-page":"00374","DOI":"10.1183\/23120541.00374-2024","article-title":"Anti-interleukin-5\/anti-interleukin-5 receptor \u03b1 treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial","volume":"10","author":"Brinkmann","year":"2024","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0046","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2025.06.017_bib0047","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.anai.2025.06.017_bib0048","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0049","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02770903.2020.1837158","article-title":"Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore","volume":"59","author":"LE","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.anai.2025.06.017_bib0050","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/JAA.S320817","article-title":"Use of Health-Related Quality of Life in clinical trials for severe asthma: a systematic review","volume":"14","author":"Lanario","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0051","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01231-2022","article-title":"Identifying and appraising outcome measures for severe asthma: a systematic review","volume":"61","author":"Rattu","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2025.06.017_bib0052","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12955-020-01593-9","article-title":"Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)","volume":"18","author":"Lanario","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.anai.2025.06.017_bib0053","doi-asserted-by":"crossref","first-page":"A4797","DOI":"10.1016\/j.chest.2024.06.2862","article-title":"Assessing the impact of asthma control questionnaire score cutoffs within the multicomponent clinical remission endpoint on clinical outcomes: traverse open-label study","volume":"166","author":"Pavord","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.anai.2025.06.017_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.883784","article-title":"An assessment of quality of life in patients with asthma through physical, emotional, social, and occupational aspects. A cross-sectional study","volume":"10","author":"Kharaba","year":"2022","journal-title":"Front Public Health"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625003096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T01:39:00Z","timestamp":1763861940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625003096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1081120625003096"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.017","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}